Oxford Science Enterprises co-leads Series B investment in BehaVR

Virtual reality mental and behavioural health companies BehaVR and OxfordVR have announced their merger, supported by an initial $13 million in Series B funding. Oxford Science Enterprises and another existing shareholder led on the funding with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures and Thornton Capital. 

We have advised Oxford Science Enterprises and the other existing shareholder on the investment that supported the merger. The combination of the two digital therapeutic companies creates the largest VR delivery platform for evidence-based digital behavioural therapies and accelerates the combined company’s growth strategy. Operating under the BehaVR brand, the comprehensive VR treatment platform will help providers, payers, and employers deliver and increase access to enhanced behavioural care.

In the UK, the team was led by corporate partner Alexandra Richardson with support from associate Aria Howorth Oram. Wilson Sonsini Goodrich & Rosati served as US counsel.